(Q36794815)

16 August 2017

1 reference

title

Anti-angiogenic therapy in renal cell cancer (English)

1 reference

16 August 2017

main subject

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

author name string

Ramaprasad Srinivasan

1

1 reference

16 August 2017

Andrew J Armstrong

2

1 reference

16 August 2017

William Dahut

3

1 reference

16 August 2017

Daniel J George

4

1 reference

16 August 2017

publication date

1 May 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

99

1 reference

16 August 2017

issue

5 Pt B

1 reference

16 August 2017

page(s)

1296-1300

1 reference

Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

The genetic basis of cancer of the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

Genetic basis of cancer of the kidney: disease-specific approaches to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

Inhibition of Cell Motility by Interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06834.X

10.1111/J.1464-410X.2007.06834.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference